Differential evaluation of autoimmune liver disease of unknown etiology, especially autoimmune hepatitis (AIH) of childhood onset. Use in combination with Liver Cytosolic Antigen Type 1 (LC-1) Antibody, IgG (2010711) when evaluating for AIH-2.
Semi-Quantitative Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube.
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.15 mL)
Severely hemolyzed or lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Less than 1:20 Normal
Liver-Kidney Microsome IgG antibody (anti-LKM), as detected by indirect immunofluorescent antibody (IFA) techniques, may be observed in patients with autoimmune hepatitis type 2 (AIH-2), AIH-2 associated with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), viral hepatitis C or D, and some forms of drug-induced hepatitis. This IFA does not differentiate among the four types of LKM antibodies (LKM-1, LKM-2, LKM-3, and a fourth type that recognizes CYP1A2 and CYP2A6 antigens). Of these, anti-LKM-1 (cytochrome P450IID6) IgG antibodies are considered specific for AIH-2.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0099270||Liver-Kidney-Microsome Abs, IgG by IFA||9838-4|
- Liver-Kidney Microsome antibody, IgG IFA
- Liver-Kidney Microsome antibody, IgG IIF
- LKM antibody, IgG IFA
- LKM antibody, IgG IIF
- LKM IgG IFA
- LKM IgG IIF